At the news
? BULLISHIMPACT 6/10 COURT-RULING filed Jul 26, 2026 at 20:00 ET
The District of North Dakota denied North Dakota's motion to stay a permanent injunction pending appeal, keeping AbbVie's win intact. The injunction blocks enforcement of a state law that AbbVie argued unlawfully interfered with the federal 340B drug pricing program, with AbbVie estimating the law cost it $10M in 2025 and would cost another $35M in 2026 in discounted sales. The denial removes near-term uncertainty and preserves AbbVie's ability to operate under the federal program without state-imposed penalties, a material positive for its 340B revenue stream.
- Court denied North Dakota's motion to stay a permanent injunction pending appeal.
- The permanent injunction blocks enforcement of a North Dakota law that AbbVie argued unlawfully interfered with the federal 340B drug pricing program.
- AbbVie estimated the law cost it $10 million in 2025 and will cost another $35 million in 2026 in discounted sales it would not make but for the law.
- The court found North Dakota unlikely to succeed on the merits, citing the law's criminal penalties and direct price regulation as key differences from other state laws.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access